Genzyme to Pay $64m to Settle Buyback Claims
The Boston Globe, August 10, 2007
Reporting that litigation between Genzyme Corporation and former shareholders involving use of "tracking stock" has settled. Genzyme will pay the plainitff class $64 million in cash subject to approval by the Court. BSF acted as lead counsel to the Class in the long running dispute.
Jonathan M. Shaw,
External Link: http://www.boston.com/business/technology/biotechnology/artic...